Condition
    Effectiveness 1/5

    Omega-3 Fatty Acids for Huntington's Disease

    Omega-3 was trialled in Huntington's disease on a plausible neuroprotective rationale. The randomised evidence is disappointing: the largest ethyl-EPA trial showed no benefit on motor function, and omega-3 should not be taken with any expectation of slowing progression.

    Overview

    Omega-3 was trialled in Huntington's disease on a plausible neuroprotective rationale. The randomised evidence is disappointing: the largest ethyl-EPA trial showed no benefit on motor function, and omega-3 should not be taken with any expectation of slowing progression.

    Verdict

    Insufficient evidence

    The main randomised trial was negative; there is no evidence omega-3 slows Huntington's progression.

    How It Works

    DHA is a structural component of neuronal membranes and EPA-derived resolvins reduce neuroinflammation — the mechanistic rationale that justified the trials, but one that did not translate into clinical benefit.

    Dosing & Protocol

    Typical dose

    Recommended dose
    If used for general cardiovascular health: 1 g combined EPA+DHA daily. No dose is supported for Huntington's itself.
    Expected timeframe
    Not applicable — no demonstrated disease benefit at any duration.

    Protocol

    form
    Not applicable
    duration
    Not applicable
    co factor
    Evidence is insufficient, and here it is close to negative: randomised trials of ethyl-EPA at 2 g/day for six to twelve months in Huntington disease, including the TREND-HD study, did not improve motor function against placebo. There is no established regimen.
    titration
    Not applicable
    starting dose
    Not applicable as a treatment

    Evidence

    What the studies say

    The TREND-HD randomised trial of ethyl-EPA found no effect on the primary motor outcome. This joins creatine (CREST-E) and coenzyme Q10 (2CARE) in a string of failed supplement trials in Huntington's disease. Nutritional support should focus on calories, protein and swallowing safety instead.

    Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study

    Score: 8/10
    2008
    rct
    n=316

    Huntington Study Group TREND-HD Investigators

    Ethyl-EPA was not beneficial in patients with Huntington disease during 6 months of placebo-controlled evaluation.

    View source

    Safety

    Caveats

    High doses carry a small atrial fibrillation and bleeding risk. Do not let supplement use displace calorie-dense nutrition, which genuinely matters in this condition.

    Less likely to help if

    Everyone with Huntington's disease, in the sense that no trial has identified a responder subgroup.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.